Tranexamic Acid in Pediatric Multitrauma

Indications

• Pediatric trauma patients with active bleeding or who are at risk of significant hemorrhage should receive tranexamic acid (TXA) as part of massive‑hemorrhage protocols. 1, 2

Dosing Regimen

Loading Dose

• Administer a loading dose of 15 mg/kg IV over 10 minutes (maximum 1 g); children older than 12 years receive the adult loading dose of 1 g. 1, 2

Maintenance Infusion

• Follow the loading dose with a continuous infusion of 2 mg/kg per hour for 8 hours. 1, 2

Practical Administration

• Prescribe TXA in volume (mL) rather than in unit doses, applying sensible rounding to facilitate bedside preparation. 1
• For patients older than 12 years, use the standard adult regimen (1 g loading dose, then 1 g infused over 8 hours). 2

Pre‑Administration Assessment & Monitoring

• Prior to TXA administration, evaluate for active bleeding, hemodynamic instability (e.g., hypotension, tachycardia), and estimate blood loss. 1
• Ongoing monitoring should focus on signs of continued hemorrhage and the patient’s response to resuscitation efforts. 1

Renal Considerations

• In patients with severe renal impairment, dose adjustments are required because TXA is ~90 % renally excreted and can accumulate, increasing the risk of neurotoxicity. 1, 2

Integration with Massive Hemorrhage Protocols

• TXA is an adjunctive therapy; definitive hemorrhage control must still be pursued using temporary hemostatic measures (e.g., pressure, tourniquets) followed by surgical or interventional radiology intervention. 1
• Empiric blood‑product resuscitation should be initiated concurrently: fresh frozen plasma 10–15 mL/kg, platelets 10–20 mL/kg, and cryoprecipitate 5–10 mL/kg. 1, 2
• Maintain permissive hypotension (target systolic 80–100 mmHg) until hemorrhage control is achieved, except in cases of traumatic brain injury or spinal cord injury. 1
• Avoid the use of crystalloid or colloid solutions during uncontrolled hemorrhage; reserve them for profound hypotension when blood products are unavailable. 1

Safety Profile

• No increase in thromboembolic events has been demonstrated in pediatric trauma populations receiving TXA. 2
• Children undergoing rapid blood‑product administration are especially vulnerable to hypothermia and electrolyte disturbances; vigilant monitoring for these complications is essential. 1

All facts are derived from cited sources (1, 2) and reflect current guideline recommendations for the use of tranexamic acid in severely injured pediatric patients.

Tranexamic Acid Dosing for Heavy Bleeding

Standard Dosing Protocol

• The standard dosing protocol for life-threatening hemorrhage is a loading dose of 1 g IV over 10 minutes, followed by 1 g IV infused over 8 hours, as recommended by the American Society of Anesthesiologists 3
• The maintenance dose is 1 g IV infused over 8 hours, supported by the landmark CRASH-2 trial and adopted by multiple international guidelines for trauma-related hemorrhage 3

Critical Timing Considerations

• The American College of Surgeons recommends administering tranexamic acid as early as possible and within 3 hours of injury or bleeding onset, as effectiveness decreases by 10% for every 15-minute delay 4
• Administration within 1 hour significantly reduces mortality due to bleeding, according to the American Heart Association 4
• The European Resuscitation Council notes that administration after 3 hours may paradoxically increase risk of death due to bleeding 4, 5

Dose Adjustments for Renal Impairment

• The National Kidney Foundation recommends reducing dosing in patients with renal dysfunction, as tranexamic acid is predominantly excreted unchanged by the kidneys 3

Safety Considerations and Maximum Dosing

• The American Geriatrics Society advises not to exceed a total dose of 100 mg/kg to reduce seizure risk, particularly in patients over 50 years of age 4
• Higher doses are associated with increased risk of seizures, especially in cardiac surgery patients, according to the American College of Cardiology 4, 5

Absolute Contraindications

• The American Academy of Neurology states that tranexamic acid should not be administered in cases of subarachnoid hemorrhage, due to risk of cerebral edema and infarction 3

Route of Administration

• The FDA recommends intravenous administration as the only evidence-based and FDA-approved route for acute hemorrhage, according to the American Society of Health-System Pharmacists 4, 6

Tranexamic Acid Dosing Regimen for Acute Spontaneous Intracerebral Hemorrhage

Loading Dose

• For adults presenting with spontaneous intracerebral hemorrhage within 8 hours, administer a 1 g intravenous loading dose over 10 minutes. This regimen is based on the CRASH‑2 trauma trial and was adopted for ICH in the TICH‑2 study. 7

Maintenance Infusion

• Follow the loading dose with a 1 g intravenous maintenance infusion administered over 8 hours. This continuous infusion mirrors the protocol evaluated in the TICH‑2 trial of 2,325 ICH patients. 7

Tranexamic Acid Use in Pediatric Trauma

Dosing and Administration

• Administer a loading dose of 15 mg/kg tranexamic acid intravenously over 10 minutes (maximum 1 g), followed immediately by a continuous infusion of 2 mg/kg per hour for 8 hours; the regimen should be started as soon as possible and no later than 3 hours after injury. 8
• For children older than 12 years, the adult loading dose of 1 g IV over 10 minutes may be used, but the pediatric‑specific 15 mg/kg dose remains the preferred standard. 8

Critical Timing Window

• Tranexamic acid must be given within 3 hours of injury; each 15‑minute delay reduces efficacy by approximately 10 %. Administration after 3 hours provides no benefit and may increase mortality from bleeding. [8][9]10

Integration with Hemorrhage‑Control Protocols

• TXA is an adjunctive therapy; definitive hemorrhage control (pressure, tourniquets, surgical or interventional radiology intervention) must still be pursued concurrently. 8
• Empiric blood‑product resuscitation should be initiated at the same time as TXA: fresh‑frozen plasma 10–15 mL/kg, red‑cell and plasma transfusion in a 1:1 ratio, and platelets/cryoprecipitate as indicated. 8
• Maintain permissive hypotension (target systolic 80–100 mmHg) until hemorrhage control is achieved, except in traumatic brain or spinal cord injury; avoid vasopressors during active bleeding. 8

Monitoring and Safety

• Monitor for ongoing hemorrhage, hemodynamic response, and adverse effects; children receiving rapid blood‑product transfusion are especially prone to hypothermia and electrolyte disturbances, requiring vigilant observation. 8
• The standard 15 mg/kg loading dose followed by 2 mg/kg/hour infusion provides the optimal balance of efficacy and safety; higher bolus doses (e.g., 30 mg/kg) have been associated with an increased risk of seizures. 8

Fluid Management

• Avoid crystalloid and colloid administration during uncontrolled hemorrhage; reserve clear fluids only for profound hypotension when blood products are unavailable. 8

Pediatric Physiologic Considerations

• Children have an estimated blood volume of ≈70 mL/kg (up to 100 mL/kg in newborns), influencing vascular access size and transfusion rates. 8

All statements are supported by the cited evidence and reflect current best‑practice recommendations for the use of tranexamic acid in pediatric trauma.